新辅助替莫唑胺联合大分割加速放疗治疗胶质母细胞瘤的2期试验
该2期试验纳入50例新诊断胶质母细胞瘤且KPS>60的成人患者,先给予2周新辅助替莫唑胺(75 mg/m2/日),继以大分割加速放疗(60 Gy/20次)联合同步及辅助替莫唑胺。主要终点为可行性和毒性,中位OS为22.3个月(95%CI 14.6-42.7),中位PFS为13.7个月(95%CI 8.0-33.3),4年OS率全组30.4%,MGMT启动子甲基化者53.3%、未甲基化者14.0%。
要点
- 新辅助替莫唑胺后行HART同步及辅助替莫唑胺方案可行,毒性可接受。
- 中位OS 22.3个月,中位PFS 13.7个月,4年OS率全组30.4%。
- MGMT启动子甲基化者4年OS率53.3%,未甲基化者14.0%。
核心结论
- 新辅助替莫唑胺方案与令人鼓舞的长期生存相关且毒性可接受,值得开展后续疗效对比试验。
研究设计与样本
- 2期试验纳入50例新诊断胶质母细胞瘤且KPS>60的成人患者。
- 新辅助替莫唑胺自术后2-3周开始,每日75 mg/m2用2周,继以HART 60 Gy/20次联合同步及辅助替莫唑胺。
- 主要终点为可行性和毒性,次要终点包括总生存(OS)和无进展生存(PFS)。
主要发现
- 中位随访时间:风险患者44.0个月,全部50例患者22.3个月。
- 除1例感染和1例HART期间进展外,所有患者按计划完成方案治疗。
- 中位OS为22.3个月(95%CI 14.6-42.7个月),中位PFS为13.7个月(95%CI 8.0-33.3个月)。
- 4年OS率全组30.4%,MGMT启动子甲基化者(n=21)53.3%,未甲基化者(n=27)14.0%。
- 1例HART期间发生5级全血细胞减少,另1例发生短暂4级肝毒性;13例接受二次手术(2例颅内感染,3例复发,4例复发合并放射性损伤,4例仅放射性损伤)。
临床怎么用
- 该方案可作为新诊断胶质母细胞瘤的潜在治疗选择,尤其需关注MGMT启动子甲基化状态对长期生存的影响。
- 治疗期间需监测血液学毒性和肝毒性,并按计划完成同步及辅助替莫唑胺。
局限性
- 为单臂2期试验,样本量50例,缺乏对照组,结论需后续对比试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We performed a phase 2 trial of neoadjuvant temozolomide (TMZ), followed by hypofractionated accelerated radiation therapy (HART) with concurrent TMZ, and adjuvant TMZ in patients with newly diagnosed glioblastoma to determine whether neoadjuvant TMZ would safely improve outcomes in this group of patients prior to subsequent cytotoxic therapy. METHODS AND MATERIALS: Adult patients with newly diagnosed glioblastoma and a Karnofsky Performance Status >60 were eligible. Neoadjuvant TMZ administration started 2 to 3 weeks from surgery at a daily dose of 75 mg/m2 for 2 weeks prior to delivery of HART (60 Gy in 20 daily fractions) with concurrent and adjuvant TMZ. The primary endpoints were feasibility and toxicity. The secondary endpoints included overall survival (OS) and progression-free survival. RESULTS: Fifty patients were accrued. The median follow-up period was 44.0 months for patients at risk and 22.3 months for all 50 patients. Except for 1 patient in whom infection developed and another patient with progression during HART, all patients completed protocol therapy as planned. The median OS and progression-free survival were 22.3 months (95% confidence interval, 14.6-42.7 months) and 13.7 months (95% confidence interval, 8.0-33.3 months), respectively. The 4-year OS rates were 30.4% for the entire cohort and 53.3% and 14.0% for patients with methylated (n=21) and unmethylated (n=27) MGMT gene promoter tumors, respectively. One patient had grade 5 pancytopenia during HART, and another patient had transient grade 4 hepatotoxicity. A second surgical procedure was performed in 13 patients: 2 had intracranial infection, 3 had recurrences, 4 had recurrences and radiation-induced damage, and 4 had only radiation-induced damage. CONCLUSIONS: This novel approach of neoadjuvant TMZ is associated with an encouraging favorable long-term survival with acceptable toxicity. A future comparative trial of the efficacy of this regimen is warranted.
引用
- Shenouda G, Souhami L, Petrecca K, et al. A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. Int J Radiat Oncol Biol Phys. 2016. PMID: 28011051. doi:10.1016/j.ijrobp.2016.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。